Oruka Therapeutics, Inc. (ORKA) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Oruka Therapeutics reported revenue of $0. Net income was -$105.4M, or -$1.85 per diluted share. Operating activities generated -$88.2M of cash, leaving -$88.4M of free cash flow. At fiscal year end, Oruka Therapeutics held $488.6M in total assets against $16.7M in total liabilities, including $46.9M of cash and equivalents.
Open the full interactive Oruka Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Oruka Therapeutics Key Stats
| Share Price | $78.19 |
|---|---|
| Market Cap | $4.92B |
| 52-Week Range | $25.51 – $113.08 |
| Shares Outstanding | 62.9 million (basic, 2026 Q2) |
Oruka Therapeutics Income Statement
| FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$5.8M | -$9.8M | -$19.3M | -$10.6M | -$7.3M | -$122.1M |
| Pre-Tax Income | -$5.6M | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$105.4M |
| Income Tax | -$167,000 | -$9,000 | — | $0 | $0 | — |
| Net Income | -$5.5M | -$9.7M | -$19.3M | -$9.9M | -$5.3M | -$105.4M |
| Diluted EPS | -$49.80 | -$24.84 | -$16.68 | -$8.28 | -$4.44 | -$1.85 |
Oruka Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$30.3M | -$29.6M | -$31.8M | -$41.2M |
| Diluted EPS | -$0.55 | -$0.65 | -$0.48 | -$0.55 |
Oruka Therapeutics Balance Sheet
| FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.4M | $49.1M | $53.4M | $42.4M | $37.4M | $46.9M |
| Current Assets | $8.5M | $50.0M | $54.4M | $42.7M | $37.6M | $343.9M |
| Total Assets | $8.5M | $50.4M | $54.9M | $43.1M | $37.9M | $488.6M |
| Current Liabilities | $926,000 | $3.5M | $3.5M | $1.1M | $637,000 | $15.4M |
| Total Liabilities | $926,000 | $3.9M | $3.9M | $1.4M | $841,000 | $16.7M |
| Shareholders' Equity | $7.6M | $46.5M | $51.0M | $41.7M | $37.0M | $471.9M |
Oruka Therapeutics Cash Flow Statement
| FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$4.8M | -$7.7M | -$18.8M | -$10.9M | -$5.0M | -$88.2M |
| Cash From Investing | -$4,000 | -$19,000 | -$43,000 | -$2,000 | $0 | -$96.7M |
| Cash From Financing | $6.6M | $48.5M | $23.1M | — | $0 | $170.3M |
| Free Cash Flow | -$4.8M | -$7.7M | -$18.8M | -$10.9M | -$5.0M | -$88.4M |
Figures from Oruka Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Oruka Therapeutics financials page for every line item.
Oruka Therapeutics Company Profile
| Ticker | ORKA |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Menlo Park, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0000907654 |
Frequently Asked Questions
What was Oruka Therapeutics' revenue in fiscal 2025?
Oruka Therapeutics (ORKA) reported revenue of $0 for fiscal 2025.
What is Oruka Therapeutics' annual revenue history?
Oruka Therapeutics' annual revenue by fiscal year: 2019: $0; 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2025: $0.
What was Oruka Therapeutics' net income in fiscal 2025?
Oruka Therapeutics reported net income of -$105.4M for fiscal 2025.
What was Oruka Therapeutics' earnings per share (EPS) in fiscal 2025?
Oruka Therapeutics' diluted EPS was -$1.85 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Oruka Therapeutics generate in fiscal 2025?
Oruka Therapeutics generated -$88.4M of free cash flow in fiscal 2025.
What was Oruka Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Oruka Therapeutics reported revenue of $0.
How many shares of Oruka Therapeutics are outstanding?
Oruka Therapeutics reported a weighted average of 62.9 million basic shares outstanding in 2026 Q2.
What is Oruka Therapeutics' market cap?
Based on its latest closing price, Oruka Therapeutics (ORKA) has a market capitalization of about $4.92B.
When does Oruka Therapeutics' fiscal year end?
Oruka Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Oruka Therapeutics headquartered?
Oruka Therapeutics lists its business address in Menlo Park, California in its SEC filings.